journal article·2020-05-11Open access

Poly(ethylene glycol)–Poly(beta-amino ester)-Based Nanoparticles for Suicide Gene Therapy Enhance Brain Penetration and Extend Survival in a Preclinical Human Glioblastoma Orthotopic Xenograft Model

Jayoung Kim, Sujan K. Mondal, Stephany Y. Tzeng, Yuan Rui, Rawan Al-kharboosh, Kristen K. Kozielski, Adip G. Bhargav, Cesar A. Garcia, Alfredo Quiñones-Hinojosa, Jordan J. Green

Abstract

Glioblastoma (GBM) is the most devastating brain cancer, and cures remain elusive with currently available neurosurgical, pharmacological, and radiation approaches. While retrovirus- and adenovirus-mediated suicide gene therapy using DNA encoding herpes simplex virus-thymidine kinase (HSV-tk) and prodrug ganciclovir has been suggested as a promising strategy, a nonviral approach for treatment in an orthotopic human primary brain tumor model has not previously been demonstrated. Delivery challenges include nanoparticle penetration through brain tumors, efficient cancer cell uptake, endosomal escape to the cytosol, and biodegradability. To meet these challenges, we synthesized poly(ethylene glycol)–modified poly(beta-amino ester) (PEG–PBAE) polymers to improve extracellular delivery and coencapsulated plasmid DNA with end-modified poly(beta-amino ester) (ePBAE) polymers to improve intracellular delivery as well. We created and evaluated a library of PEG–PBAE/ePBAE nanoparticles (NPs) for effective gene therapy against two independent primary human stem-like brain tumor initiating cells, a putative target to prevent GBM recurrence. The optimally engineered PEG–PBAE/ePBAE NP formulation demonstrated 54 and 82% transfection efficacies in GBM1A and BTIC375 cells respectively, in comparison to 37 and 66% for optimized PBAE NPs without PEG. The leading PEG–PBAE NP formulation also maintained sub-250 nm particle size up to 5 h, while PBAE NPs without PEG showed aggregation over time to micrometer-sized complexes. The comparative advantage demonstrated in vitro successfully translated into improved in vivo diffusion, with a higher amount of PEG–PBAE NPs penetrating to a distance of 2 mm from the injection site. A significant increase in median survival from 53.5 to 67 days by PEG–PBAE/pHSV-tk NP and systemic ganciclovir treatment compared to a control group in orthotopic murine model of human glioblastoma demonstrates the potential of PEG–PBAE-based NPs as an effective gene therapy platform for the treatment of human brain tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, United States

Translational Tissue Engineering Center and Institute for NanoBioTechnology, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, United States

Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida 32224, United States

Max Planck Institute for Intelligent Systems, Heisenbergstrasse 3, Stuttgart 70569, Germany

Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, Minnesota 55904, United States

Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, Maryland 21231, United States

Department of Oncology, the Sidney Kimmel Comprehensive Cancer, and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, United States

Department of Ophthalmology, Department of Materials Science and Engineering, and Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21231, United States

Funding

Howard Hughes Medical Institute · Samsung · National Institutes of Health · Mayo Clinic · Bloomberg?Kimmel Institute for Cancer Immunotherapy · Clinician Investigator award

References (53)

Show source-provided references
1. 10.1021/nn501197v10.1021/nn501197v ↗
2. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
3. 10.1200/JCO.2005.04.967610.1200/JCO.2005.04.9676 ↗
4. 10.3390/brainsci712016610.3390/brainsci7120166 ↗
5. 10.3322/caac.2013810.3322/caac.20138 ↗
6. 10.2741/s26110.2741/s261 ↗
7. 10.1016/j.expneurol.2007.03.01610.1016/j.expneurol.2007.03.016 ↗
8. 10.1093/carcin/bgu24310.1093/carcin/bgu243 ↗
9. 10.1200/JCO.2003.21.13.250810.1200/JCO.2003.21.13.2508 ↗
10. 10.1038/sj.onc.120723210.1038/sj.onc.1207232 ↗
11. Moolten F. L. · Cancer Res. · 1986 · 46 · 5276
12. 10.1002/jgm.263010.1002/jgm.2630 ↗
13. 10.1016/j.radonc.2012.07.01110.1016/j.radonc.2012.07.011 ↗
14. 10.1016/S0002-9394(00)00442-610.1016/S0002-9394(00)00442-6 ↗
15. 10.1038/nrd177510.1038/nrd1775 ↗
16. 10.1002/jgm.301510.1002/jgm.3015 ↗
17. 10.1016/j.biomaterials.2011.04.01610.1016/j.biomaterials.2011.04.016 ↗
18. 10.1158/0008-5472.CAN-19-162410.1158/0008-5472.CAN-19-1624 ↗
19. 10.1021/acs.nanolett.8b0039010.1021/acs.nanolett.8b00390 ↗
20. 10.1016/j.biomaterials.2019.04.02010.1016/j.biomaterials.2019.04.020 ↗
21. 10.1021/nn500704t10.1021/nn500704t ↗
22. 10.1016/j.actbio.2016.05.04010.1016/j.actbio.2016.05.040 ↗
23. 10.1016/j.biomaterials.2016.05.02510.1016/j.biomaterials.2016.05.025 ↗
24. 10.1016/j.jconrel.2017.03.38410.1016/j.jconrel.2017.03.384 ↗
25. 10.1002/btm2.1001910.1002/btm2.10019 ↗
26. 10.1021/bc400232210.1021/bc4002322 ↗
27. 10.1021/mp300417610.1021/mp3004176 ↗
28. 10.1021/ja400237610.1021/ja4002376 ↗
29. 10.1016/j.biomaterials.2009.10.01210.1016/j.biomaterials.2009.10.012 ↗
30. 10.1021/acs.biomac.8b0064010.1021/acs.biomac.8b00640 ↗
31. 10.1021/nn504905q10.1021/nn504905q ↗
32. 10.1158/0008-5472.CAN-04-136410.1158/0008-5472.CAN-04-1364 ↗
33. 10.1038/onc.2015.45210.1038/onc.2015.452 ↗
34. 10.1016/j.jconrel.2020.01.00310.1016/j.jconrel.2020.01.003 ↗
35. 10.1021/acs.molpharmaceut.8b0095910.1021/acs.molpharmaceut.8b00959 ↗
36. 10.7150/thno.2683710.7150/thno.26837 ↗
37. 10.1039/C9NR04795F10.1039/C9NR04795F ↗
38. 10.1158/1078-0432.CCR-13-141510.1158/1078-0432.CCR-13-1415 ↗
39. 10.3791/208210.3791/2082 ↗
40. 10.1111/j.1365-2818.1987.tb02837.x10.1111/j.1365-2818.1987.tb02837.x ↗
41. Rubsam L. Z. · Cancer Res. · 1999 · 59 · 669
42. 10.1038/sj.onc.120528010.1038/sj.onc.1205280 ↗
43. 10.1021/acsnano.5b0382310.1021/acsnano.5b03823 ↗
44. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
45. 10.1002/adhm.20140080010.1002/adhm.201400800 ↗
46. 10.2147/IJN.S23116710.2147/IJN.S231167 ↗
47. 10.1126/scitranslmed.300359410.1126/scitranslmed.3003594 ↗
48. 10.1038/sj.gt.330090010.1038/sj.gt.3300900 ↗
49. 10.1016/j.ymthe.2005.02.01010.1016/j.ymthe.2005.02.010 ↗
50. 10.1002/adhm.20120025710.1002/adhm.201200257 ↗
51. 10.1002/jbm.a.3461610.1002/jbm.a.34616 ↗
52. 10.1016/j.jconrel.2017.07.00910.1016/j.jconrel.2017.07.009 ↗
53. 10.1002/(SICI)1097-0215(19991029)83:3<374::AID-IJC13>3.0.CO;2-#10.1002/(SICI)1097-0215(19991029)83:3<374::AID-IJC13>3.0.CO;2-# ↗